Eli Lilly's Cheaper Insulin Can Fill in for Sanofi's Lantus (1) – Bloomberg Law

By Celine Castronuovo
Diabetic patients will now have easier access to insulin after the FDA on Thursday approved Eli Lilly & Co.’s biosimilar as an interchangeable with the biologic drug.
Rezvoglar, which the Food and Drug Administration previously approved in December 2021, can now be swapped out as a substitute for Sanofi’s Lantus at the pharmacy counter without prior authorization from a certified medical prescriber.
Eli Lilly’s drug is the second interchangeable insulin product approved by the FDA—part of the agency’s efforts to offer and ease access to lower-cost treatments for patients.
“This approval furthers FDA’s longstanding commitment to support a competitive …
To read the full article log in.
Learn more about a Bloomberg Law subscription.


Leave a Reply

Your email address will not be published. Required fields are marked *